Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josh Hanson

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT studyPhyo Pyae Nyein, Margaret Borok, Nnakelu Eriobu, et al.
The Lancet. Global Health|May 18, 2023
Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant dataTobias Broger, Lisa Koeppel, Helena Huerga, et al.
The Lancet. Infectious Diseases|November 20, 2021
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysisAshar Dhana, Yohhei Hamada, Andre P Kengne, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT studyPhyo Pyae Nyein, Margaret Borok, Nnakelu Eriobu, et al.
The Lancet. Global Health|May 18, 2023
Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant dataTobias Broger, Lisa Koeppel, Helena Huerga, et al.
The Lancet. Infectious Diseases|November 20, 2021
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysisAshar Dhana, Yohhei Hamada, Andre P Kengne, et al.
Pageof 15